Madrigal Pharmaceuticals, Inc. (MDGL)
Company Info
Highlights
$6.80B
-$17.83
$317.38M
$306.81M
-$376.15M
$200.63 - $377.46
$421.93
21.04%
13.64
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Madrigal Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Madrigal Pharmaceuticals, Inc. (MDGL) returned -4.51% year-to-date (YTD) and 42.39% over the past 12 months. Over the past 10 years, MDGL delivered an annualized return of 13.84%, outperforming the S&P 500 benchmark at 10.45%.
MDGL
-4.51%
-6.15%
-15.99%
42.39%
26.60%
13.84%
^GSPC (Benchmark)
-3.77%
3.72%
-5.60%
8.55%
14.11%
10.45%
Monthly Returns
The table below presents the monthly returns of MDGL, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 8.50% | 1.93% | -2.94% | 0.81% | -11.76% | -4.51% | |||||||
| 2024 | -6.34% | 8.99% | 13.06% | -23.60% | 15.75% | 18.63% | 1.61% | -13.18% | -14.13% | 22.20% | 26.55% | -5.98% | 33.36% |
| 2023 | -0.69% | -5.98% | -10.61% | 28.79% | -10.77% | -17.03% | -11.13% | -12.32% | -18.87% | -10.04% | 54.74% | 13.81% | -20.28% |
| 2022 | -32.05% | 61.25% | 5.68% | -28.66% | -5.16% | 7.82% | -12.24% | 14.80% | -9.89% | 8.97% | -1.00% | 313.99% | 242.52% |
| 2021 | 6.83% | 2.05% | -3.48% | 16.35% | -17.49% | -13.26% | -10.36% | -5.23% | -3.58% | -2.56% | 6.38% | 2.45% | -23.77% |
| 2020 | -8.88% | 3.79% | -22.53% | 25.34% | 38.65% | -2.39% | -9.40% | 4.96% | 10.24% | 7.18% | -8.22% | -4.81% | 22.02% |
| 2019 | 2.70% | 13.41% | -4.59% | -15.31% | -12.90% | 13.43% | -16.72% | 6.20% | -6.99% | 7.20% | 19.76% | -17.69% | -19.17% |
| 2018 | 61.70% | -15.08% | -7.34% | -3.11% | 134.72% | 5.30% | -8.10% | -6.93% | -10.48% | -10.87% | -39.41% | -2.53% | 22.80% |
| 2017 | 2.55% | 2.09% | -1.28% | 7.14% | -7.76% | 6.83% | -4.67% | 10.19% | 163.35% | 11.14% | 0.70% | 82.34% | 516.04% |
| 2016 | -30.43% | -7.10% | 5.49% | 66.67% | -12.50% | -25.66% | -17.65% | 53.87% | 9.88% | 30.13% | -2.97% | -6.93% | 20.94% |
| 2015 | -10.19% | 0.84% | -19.17% | 15.98% | -4.89% | 4.21% | -4.93% | -5.66% | -13.00% | -61.49% | -36.13% | -17.74% | -86.72% |
| 2014 | 1.91% | 15.73% | -30.26% | -2.32% | -2.61% | -0.24% | -3.42% | 1.27% | -24.75% | -1.66% | 7.09% | -16.40% | -49.43% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 76, MDGL is among the top 24% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Madrigal Pharmaceuticals, Inc. (MDGL) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Madrigal Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Madrigal Pharmaceuticals, Inc. was 98.40%, occurring on Feb 11, 2016. The portfolio has not yet recovered.
The current Madrigal Pharmaceuticals, Inc. drawdown is 28.11%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.4% | Jan 29, 2013 | 766 | Feb 11, 2016 | — | — | — |
| -87.64% | Oct 8, 2007 | 351 | Feb 27, 2009 | 981 | Jan 22, 2013 | 1332 |
| -51.43% | Jun 5, 2007 | 58 | Aug 24, 2007 | 28 | Oct 4, 2007 | 86 |
| -18.88% | Feb 12, 2007 | 40 | Apr 10, 2007 | 38 | Jun 4, 2007 | 78 |
| -4.32% | Jan 24, 2013 | 1 | Jan 24, 2013 | 1 | Jan 25, 2013 | 2 |
Volatility
Volatility Chart
The current Madrigal Pharmaceuticals, Inc. volatility is 11.63%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Madrigal Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Madrigal Pharmaceuticals, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 47.1% positive surprise.
Valuation
The Valuation section provides an overview of how Madrigal Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for MDGL compared to other companies in the Biotechnology industry. MDGL currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MDGL relative to other companies in the Biotechnology industry. Currently, MDGL has a P/S ratio of 40.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MDGL in comparison with other companies in the Biotechnology industry. Currently, MDGL has a P/B value of 10.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |